近年、がん治療標的としてのデルタ様リガンド3(DLL3)の発見は、標的治療の展望における重要な決定的瞬間として浮上しています。非がんとがんの両方のシナリオにおけるDLL3の役割と経路を理解することで、画期的な治療選択肢としてのDLL3の可能性が明らかになりました。DLL3は、これまで非がん性細胞プロセスにおける役割で知られていた膜貫通型タンパク質であり、さまざまな悪性腫瘍、特に小細胞肺がん、膀胱がん、消化器膵臓がんなどの神経内分泌がんにおいて過剰発現するため、有望ながん治療標的として浮上しています。
目次
1. Research Methodology
2. Introduction to DLL3 Targeted Therapies
2.1 Overview
2.2 History and Evolution of DLL3 Targeted Therapies
3. Role of DLL3 As Diagnostic and Prognostic Markers
3.1 Diagnostic Biomarker
3.2 Prognostic Biomarker
4. DLL3 Targeting Approaches, Mechanism and Commercial Aspects
4.1 Antibody Drug Conjugates
4.2 Antibodies
4.3 Cell therapies
4.4 Antibody Radionuclide Conjugates
4.5 Antibody Photoabsorber/Photosensitizer Conjugate
5. Global DLL3 Targeted Therapies Research and Market Trends By Indication
5.1 Small Cell Lung Cancer
5.2 Large Cell Neuroendocrine Cancer
5.3 Neuroendocrine Prostate Cancer
5.4 Gastroenteropancreatic Neuroendocrine Tumors
5.5 Glioma
6. DLL3 Targeted Therapies Proprietary Platforms
6.1 Platforms Used To Develop DLL3 Targeted Therapies
6.2 Potential Platforms for DLL3 Targeted Therapies Development
7. Global DLL3 Targeted Drugs Clinical Trials Overview
7.1 By Company
7.2 By Fast Track Status
7.3 By Indication
7.4 By Location
7.5 By Patient Segment
7.6 By Phase
8. Global DLL3 Targeted Drugs Clinical Trials By Company, Indication and Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Preregistration
9. DLL3 Targeted Therapies Market Trends and Clinical Trials Insights
9.1 Current Market Trends, Developments and Clinical Trials Assessment
9.2 Future Commercialization Opportunity
10. DLL3 Targeted Therapies Research and Market Trends by Region
10.1 US
10.2 UK
10.3 EU
10.4 Canada
10.5 Australia
10.6 China
11. DLL3 Targeted Therapies Market Dynamics
11.1 Favorable Market and Clinical Development Parameters
11.2 Challenges and Restraints
12. Key Companies Involved In Research and Development Of DLL3 Targeted Therapies
12.1 Abdera Therapeutics
12.2 Allogene Therapeutics
12.3 Amgen
12.4 Boehringer Ingelheim
12.5 Chugai Pharmaceutical
12.6 Gensun Biopharma
12.7 Harpoon Therapeutics
12.8 ImaginAb Inc
12.9 Legend Biotech
12.10 Molecular Partners
12.11 Phanes Therapeutics
12.12 Qilu Pharmaceutical
12.13 Shanghai Affinity Biopharmaceutical
12.14 ZAI Lab
List of Figures
Figure 4-1: Antibody Drug Conjugates - Mechanism Of Action
Figure 4-2: BiTE - Amgen
Figure 4-3: HPN328 - Structure
Figure 4-4: Rova-IR700 - Mechanism
Figure 5-1: DLL3 - Small Cell Lung Cancer
Figure 5-2: DeLLphi-301 Phase 2 Study - Initiation and Completion Years
Figure 5-3: DeLLphi-304 Phase 2 Study - Initiation and Completion Years
Figure 5-4: DAREONandtrade;-5 Phase 2 Study - Initiation and Completion Years
Figure 5-5: PT217X1101 Phase 1 Study - Initiation and Completion Years
Figure 5-6: HPN328 Phase 1 Study - Initiation and Completion Years
Figure 5-7: LB2102-1001 Phase 1 Study - Initiation and Completion Years
Figure 5-8: NCT05507593 Phase 1 Study - Initiation and Completion Years
Figure 5-9: DLL3 - Large Cell Neuroendocrine Cancer
Figure 6-1: T-Charge Platform - Features
Figure 6-2: BiTEandreg; Antibody Construct
Figure 6-3: TMALIN - ADC Advantages
Figure 6-4: TMALIN - ADC Structure
Figure 6-5: TriTAC - T-Cell Engagers Structure
Figure 6-6: TriTAC - Advantages
Figure 6-7: PACbodyandtrade; Platform
Figure 6-8: ATACCbodyandtrade; Platform
Figure 6-9: SPECpairandtrade; Platform
Figure 6-10: ROVEr Platform - Process
Figure 6-11: RPT - Advantages
Figure 6-12: Dual-Ig Technology - Antibody Structure and Mechanism
Figure 6-13: AlloCAR T - Process
Figure 6-14: AlloCAR T - Features
Figure 6-15: Alluminoxandtrade; Platform - Drug Structure
Figure 6-16: Rakuten Medical - Photoimmunotherapy Process
Figure 7-1: Global - DLL3 Targeted Drugs Clinical Trials By Company (Number), 2024
Figure 7-2: Global - DLL3 Targeted Drugs Clinical Trials By Fast Track Status (Number), 2024
Figure 7-3: Global - DLL3 Targeted Drugs Clinical Trials By Indication (Number), 2024
Figure 7-4: Global - DLL3 Targeted Drugs Clinical Trials By Location (Number), 2024
Figure 7-5: Global - DLL3 Targeted Drugs Clinical Trials By Patient Segment (Number), 2024
Figure 7-6: Global - DLL3 Targeted Drugs Clinical Trials By Phase (Number), 2024
Figure 11-1: DLL3 Targeted Therapies - Market Drivers and Opportunities
Figure 11-2: DLL3 Targeted Therapies - Market Challenges and Restraints
List of Tables
Table 5-1: Large Cell Neuroendocrine Cancer - Candidates In Clinical Trials
Table 5-2: Neuroendocrine Prostate Cancer - Candidates IIn Clinical Trials
Table 5-3: Gastroenteropancreatic Neuroendocrine Tumors - Candidates In Clinical Trials
Table 5-4: Glioma - Candidates In Clinical Trials
Table 10-1: US - FDA Designated DLL3 Targeted Therapies
